1.    For our hearts, Q1+Q10 capsule with Vitamin B1 and selenium
2.    Celsus Q1+Q10 Vital capsule 30 and 60 pcs
3.    Celsus Q1+Q10 spray

Our combined Q1 and Q10 products are unique in the whole word!

Some scientific background for Celsus Q1+Q10 products

Coenzyme Q10 (CoQ10) is produced by the human body and is necessary for the basic functioning of cells. Coenzyme Q1 (CoQ1 or NADH) is a natural substance found in most life forms and is necessary for energy production.

CoQ10 and NADH are the key members of the electron transfer chain in mitochondria. The passage of electrons along the electron transport chain is coupled to the formation of ATP by the process known as oxidative phosphorylation. Coenzyme Q-10 is not an antioxidant although it is characterized as such in all of the commercial available products. Co-enzyme Q-10 is the oxidized form of this substance and an oxidant can never ever be an antioxidant. However, when CoQ10 is absorbed into the organism it is reduced by NADH and, thus, becomes an antioxidant. In other words, NADH makes Coenzyme Q-10 in the body into an antioxidant; hence, Coenzyme Q-10 needs NADH to become effective. Additionally, CoQ10 concentrations may be increased with NADH supplements.

Coenzyme Q10 deficiency
CoQ10 levels are reported to decrease with age and to be low in patients with some chronic diseases such as heart conditions, muscular dystrophies, Parkinson's disease, cancer, diabetes, and HIV/AIDS. Coenzyme Q10 is normally produced by the human body, although deficiency may occur in patients with impaired CoQ10 biosynthesis due to severe metabolic or mitochondrial disorders, not enough dietary CoQ10 intake, or too much CoQ10 use by the body. Depending on the cause of CoQ10 deficiency, supplementation or increased dietary intake of CoQ10 and the vitamins and minerals needed to produce CoQ10 may be effective.

Evidences for application CoQ10 and/or CoQ1 supplements:
•    Heart attack
•    High blood pressure
•    Angina
•    Age-related macular degeneration
•    Alzheimer's disease
•    Parkinson's disease
•    Anthracycline chemotherapy heart toxicity
•    Chronic fatigue syndrome
•    Mitochondrial diseases
•    Muscular dystrophies
•    Type-2 diabetes
(See more specific information about the evidences in the pages of Celsus’ products and the reference list find here).

FOR OUR HEARTS, Q1+Q10 CAPSULE WITH B1 AND SELENIUM

One of the best food supplements for heart protection in Hungary

Why this product is our best?
There are a few important new clinical studies were published in the last 2-3 years. The most important one was published by Swedish clinicians last year (Link reference list 7-hez).

The background of the study was the selenium and coenzyme Q10 are essential for functioning of cells. Low cardiac contents of selenium and coenzyme Q10 have been shown in patients with cardiomyopathy, but inconsistent results are published on the effect of supplementation of the two components separately. A vital relationship exists between the two substances to obtain optimal function of the cell. However, reports on combined supplements were lacking before the study.

A 5-year prospective randomized double-blind placebo-controlled trial among Swedish citizens aged 70 to 88 was performed in 443 participants given combined supplementation of 200 microgram organic selenium and 200 mg coenzyme Q10 or a placebo.

During a follow up time of 5.2 years a significant reduction of cardiovascular mortality was found in the active treatment group (mortality: 5.9%) vs. the placebo group (mortality: 12.9%). In echocardiography a significant better cardiac function score was found in the active supplementation compared to the placebo group (P=0.03). The positive effects could also be seen in NT-proBNP levels and on echocardiography.

Our conclusion was that long-term supplementation of selenium and coenzyme Q10 together reduces cardiovascular mortality. We thought the Q1 and Vitamin B1 can enhance the effect of Q10 and selenium. Finally we decided to develop a new effective product which is the FOR OUR HEART capsule.

CELSUS Q1+Q10 VITAL CAPSULE 30 AND 60 PCS

Simply the easiest way to supply Q1 and Q10 together


Evidences for Q1 and Q10 supplementation
•  The application of Q1 and Q10 together is more effective than the Q1 and Q10 application alone.
•  The Q1 and Q10 have important role in the mitochondrial functions.
•  The Q1 and Q10 supplementation can facilitate the energy syntheses in the mitochondrium.

Suggestion for application CoQ10 and CoQ1 spray:
•   Heart attack: There is preliminary human study of CoQ10 given to patients within three days after a heart attack. The application of CoQ10 was helpful for the patients.
•   High blood pressure: Preliminary research suggests that CoQ10 causes decreases in blood pressure.
•  Angina: Preliminary human studies suggest that CoQ10 may reduce angina and improve exercise tolerance in people with clogged heart arteries.
•  Alzheimer's disease: Promising preliminary evidence suggests that CoQ10 and/or CoQ1 supplements may slow down dementia in people with Alzheimer's disease.
• Parkinson's disease: There is promising human evidence for the use of CoQ10 and/or CoQ1 in the treatment of Parkinson's disease.
• Mitochondrial diseases: CoQ10 and/or CoQ1 is often recommended for patients with mitochondrial diseases, including myopathies, and encephalomyopathies. CoQ10 may help improve function in children with maternally-inherited diabetes and deafness.
• Muscular dystrophies: Preliminary studies in patients with muscular dystrophy taking CoQ10 supplements describe improvements in exercise capacity, heart function, and overall quality of life.

CELSUS Q1+Q10 SPRAY

The only one food supplement spray in the world which contains Q1 and Q10 together

Prior to recent discoveries NADH is rather unstable. It would have been expected that this substance would be hydrolized in the gastric juice within a few seconds. One possibility to solve this problem is to use gastric juice resistant capsules. The other possibility is to use liquid form. For this product the sublingual spray form of NADH was chosen to maximize the absorption and optimize bioavailability of the CoQ1.
We wanted evidence that the bioavailability of the components of spray is really higher than other forms and an absorption pilot study was performed.


Suggestion for application CoQ10 and CoQ1 spray:
• Heart attack: There is preliminary human study of CoQ10 given to patients within three days after a heart attack. The application of CoQ10 was helpful for the patients.
• High blood pressure: Preliminary research suggests that CoQ10 causes decreases in blood pressure.
• Angina: Preliminary human studies suggest that CoQ10 may reduce angina and improve exercise tolerance in people with clogged heart arteries.
• Alzheimer's disease: Promising preliminary evidence suggests that CoQ10 and/or CoQ1 supplements may slow down dementia in people with Alzheimer's disease.
• Parkinson's disease: There is promising human evidence for the use of CoQ10 and/or CoQ1 in the treatment of Parkinson's disease.
• Mitochondrial diseases: CoQ10 and/or CoQ1 is often recommended for patients with mitochondrial diseases, including myopathies, and encephalomyopathies. CoQ10 may help improve function in children with maternally-inherited diabetes and deafness.
• Muscular dystrophies: Preliminary studies in patients with muscular dystrophy taking CoQ10 supplements describe improvements in exercise capacity, heart function, and overall quality of life.



Pilot study about the CoQ10 absorption from Q1Q10 spray

Coenzyme Q10 (CoQ10) is produced by the human body and is necessary for the basic functioning of cells. Coenzyme Q1 (CoQ1 or NADH) is a natural substance found in most life forms and is necessary for energy production. CoQ10 and NADH are the key members of the electron transfer chain in mitochondria. The passage of electrons along the electron transport chain is coupled to the formation of ATP by the process known as oxidative phosphorylation. Coenzyme Q10 is not an antioxidant although it is characterized as such in all of the commercial available products. Coenzyme Q10 is the oxidized form of this substance and an oxidant can never ever be an antioxidant. However, when CoQ10 is absorbed into the organism it is reduced by NADH and, thus, becomes an antioxidant. In other words, NADH makes Coenzyme Q10 in the body into an antioxidant; hence, Coenzyme Q-10 needs NADH to become effective. Additionally, CoQ10 concentrations may be increased with NADH supplements.

Coenzyme Q10 levels are reported to decrease with age and to be low in patients with some chronic diseases such as heart conditions, muscular dystrophies, Parkinson's disease, cancer and diabetes. Coenzyme Q10 is normally produced by the human body, although deficiency may occur in patients with impaired CoQ10 biosynthesis due to severe metabolic or mitochondrial disorders, not enough dietary CoQ10 intakes or too much CoQ10 use by the body. Depending on the cause of CoQ10 deficiency, supplementation or increased dietary intake of CoQ10 and the vitamins and minerals needed to produce CoQ10 may be effective.

Prior to recent discoveries CoQ1 is rather unstable and, hence, not capable of being absorbed by the intestines of the human body. It would have been expected that this substance would be hydrolized in the gastric juice within a few seconds. The previously described problem is the cause why the sublingual spray form of CoQ1 and CoQ10 was chosen by Celsus Ltd. to maximize the absorption and optimize bioavailability of the CoQ1.

The aim of this study was to determine the absorbance and bioavailability of CoQ10 from Q1Q10 sublingual spray. The study was performed between July 1 and August 31 2010 in the University of Debrecen. Six healthy participants (age between 25 and 41 years) were observed based on the clinical study which was performed to determine the CoQ10 absorbance from Contox3 sublingual spray. However, our study was implemented with a CoQ10 absorbance test using Q1Q10 capsule from the same company, also. We determined the absorbed CoQ10 from the plasma of participants using the standards published by Yamashita and Yamamoto in the Analytical Biochemistry (1997). Unfortunately, we do not have useful analytical tool to determine the plasma CoQ1 content.

Figure 1. Changes of plasma CoQ10 content after application Q1Q10 spray (--), or capsule (--) (normalized to control, x-axis in min).

First, we determined the absorption kinetics of the CoQ10 from Q1Q10 spray and capsule. The Figure 1. shows the representative normalized time kinetic curves after application of Q1Q10 spray or capsule. The slope of the changes of plasma CoQ10 content was faster and the peak of plasma CoQ10 content was significant higher after Q1Q10 spray application than after Q1Q10 capsule.
In the next step we determined the changes of the plasma peak CoQ10 content after the application of Q1Q10 spray and capsule (Figure 2.). The changes of the plasma peak CoQ10 was significantly higher after application of Q1Q10 spray (1.35±0.08, mean±standard deviation) than capsule (1.18±0.06) in every participant. This means that the absorbance of CoQ10 was approximately 15 % more effective after spray than capsule.

Figure 2. The changes of the plasma peak CoQ10 content after the application of Q1Q10 spray (--), or capsule (--) in six participants (normalized to control, x-axis No. of participant).

SUMMARY OF OUR FINDINGS:
The Celsus Ltd. finally produced a CoQ10 containing food supplement where the CoQ10 has an increased bioavailability. The spray form of their products is more effective than capsule.

NOTE:
It seems that the changes of plasma peak CoQ10 content was poor, but do not forget that all participants are healthy with a normal plasma CoQ10 content.

References:
1. Contox3, study . http://www.contoxtrade.hu/letolt/szakmai_inform (Hungarian)
2. Cortes E.P, Mohinder G., Patel M., Mundia A., and Folkers K.  Study of Administration of coenzyme Q10 to Adriamycin treated cancer patients.  In:Biomedical and Clinical Aspects of Coenzyme Q (1977).  Folkers K., Yamamura Y. (eds) Elsevier, Amsterdam, pp 267-273.
3. Eighth International Symposium on Biomedical and Clinical Aspects of Coenzyme Q (1994) Littarru G.P., Battino M. , Folkers K. (Eds) The Molecular Aspects of Medicine, Vol. 15 (Supplement), pp S1-S294.
4. Ernster L. (1977) Facts and ideas about the function of coenzyme Q10 in the Mitochondria.  In:  Folkers K., Yamamura Y. (eds)  Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam, pp 15-8.
5. Folkers K., Langsjoen Per H.,Willis R., Richardson P., Xia L.,Ye C., Tamagawa H. (1990) Lovastatin decreases coenzyme Q levels in humans.  Proc. Natl. Acad Sci. Vol. 87, pp.8931-8934.
6. Folkers K., Vadhanavikit S., Mortensen S.A. (1985) Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. In: Proc. Natl. Acad. Sci., U.S.A., vol. 82(3), pp 901-904.
7. Gian Paolo Littarru (1994) Energy and Defense. Facts and perspectives on CoenzymeQ10 in biology and medicine. Casa Editrice Scientifica Internazionale, pp 1-91.
8. Judy W.V., Hall J.H., Toth P.D., Folkers K. (1986) Double blind-double crossover study of coenzyme Q10 in heart failure.  In:  Folkers K., Yamamura Y. (eds) Biomedical and clinical aspects of coenzyme Q, vol. 5.  Elsevier, Amsterdam, pp 315-323.
9. Langsjoen P. H., Langsjoen P. H., Willis R., Folkers K. (1994) Treatment  of essential hypertension with coenzyme Q10.  In:  Eighth International Symposium on Biomedical and Clinical Aspects of Coenzyme Q (1994) Littarru G.P., Battino M. , Folkers K. (Eds) The Molecular Aspects of Medicine, Vol. 15 (Supplement), pp S287-S294.
10. Langsjoen P. H., Langsjoen, P. H., Folkers, K. (1989) Long term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.  In:  The American Journal of Cardiology, Vol. 65, pp 521 - 523.
11. Langsjoen Per.H., Vadhanavikit S., Folkers K. (1985) Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. In:  Proc. Natl.  Acad. of Sci., U.S.A., vol. 82, pp 4240-4244.
12. Mellors A., Tappel A.L. (1966) The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol. J. Biol. Chem., vol. 241, pp 4353-4356.
13. Mitchell P. (1988) Respiratory chain systems in theory and practice.  In:  Advances in Membrane Biochemistry and Bioenergetics, Kim C.H., et al. (eds), Plenum Press, New York, pp 25-52.
14. Mitchell P. (1991) The vital protonmotive role of coenzyme Q.  In:  Folkers K., Littarru G.P., Yamagami T. (eds) Biomedical and Clinical Aspects of Coenzyme Q, vol. 6, Elsevier, Amsterdam, pp 3-10.
15. Mortensen S.A., Vadhanavikit S., Folkers K. (1984) Deficiency of coenzyme Q10 in myocardial failure. In: Drugs Exptl. Clin. Res. X(7) 497-502.
16. Yamashita S., Yamamoto Y (1997) Simultaneous Detection of Ubiquinol and Ubiquinone in Human Plasma as a Marker of Oxidative Stress. Analytical Biochemistry 250, 66–73



Reference list:
1. Crane, F; Hatefi, Y; Lester, R; Widmer, C (1957). "Isolation of a quinone from beef heart mitochondria". Biochimica et Biophysica Acta 25 (1): 220–1. doi:10.1016/0006-3002(57)90457-2. PMID 13445756.
2. Mayo Clinic Drugs and Supplements: Coenzyme Q10 . Retrieved 13 November 2008.
3. Rosenfeldt, F L; Haas, S J; Krum, H; Hadj, A; Ng, K; Leong, J-Y; Watts, G F (2007). "Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials". Journal of Human Hypertension 21 (4): 297–306. doi:10.1038/sj.jhh.1002138. PMID 17287847.
4. Bhagavan, Hemmi N.; Chopra, Raj K. (2006). "Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics". Free Radical Research 40 (5): 445–53. doi:10.1080/10715760600617843. PMID 16551570.
5. Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K (August 2007). "Improvement in intestinal coenzyme Q10 absorption by food intake". Yakugaku Zasshi 127 (8): 1251–4. doi:10.1248/yakushi.127.1251. PMID 17666877.[verification needed]
6. Zmitek et al. (2008) Agro Food Ind. Hi Tec. 19, 4, 9. – Improving the bioavailability of CoQ10
7. Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U.: Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2012 May 22.
8. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve. 2010 Nov;42(5):739-48. doi: 10.1002/mus.21758.
9. ClinicalTrials.gov NCT00740714 Effects of Coenzyme Q10 (CoQ) in Parkinson Disease (QE3)
10. Tanguy S, Grauzam S, de Leiris J, Boucher F. Impact of dietary selenium intake on cardiac health: experimental approaches and human studies. Mol Nutr Food Res. 2012 Jul;56(7):1106-21. doi: 10.1002/mnfr.201100766.
11. McKeag NA, McKinley MC, Woodside JV, Harbinson MT, McKeown PP. The role of micronutrients in heart failure.J Acad Nutr Diet. 2012 Jun;112(6):870-86. doi: 10.1016/j.jand.2012.01.016.
12. Glancy B, Balaban RS. Role of mitochondrial Ca2+ in the regulation of cellular energetics. Biochemistry. 2012 Apr 10;51(14):2959-73. doi: 10.1021/bi2018909. Epub 20